Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
JAMA Surgery · 01.05.2025 · 160 (5) · 565
DOI: 10.1001/jamasurg.2025.0220 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Surgery, erschienen am 01.05.2025. Verfasst von Xufeng Guo und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Immunotherapy. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The association of neoadjuvant chemoimmunotherapy (NCIT) vs chemoradiotherapy (NCRT) with tumor downstaging and survival in locally advanced esophageal squamous cell carcinoma (ESCC) remains unclear because of limited evidence.
Objective
To compare the associations of NCIT and NCRT with tumor regression and long-term survival in patients with locally advanced ESCC. Design, Setting, and Participants In this comparative effectiveness research study, from January 2016 to March 2023, patients with locally advanced ESCC who underwent esophagectomy following NCRT or NCIT were identified from a prospective database of 8 high-volume esophageal surgery centers in China. Follow-up began on the date of surgery and continued until the last recorded contact or March 2024, whichever occurred first. Data were analyzed between April and September 2024. Main Outcomes and Measures The primary end points were 2-year overall survival (OS) and disease-free survival (DFS). Secondary end points included major pathologic response (MPR) and pathologic complete response (pCR). Cox proportional hazard regression analysis was used to investigate the risk factors for OS and DFS.
Results
The study included 1428 patients (median [IQR] age, 63 [57-68] years; 1184 men [82.9%]), with 704 patients in the NCRT group and 724 patients in the NCIT group. After propensity score matching, there were 532 patients in each group. The 2-year OS (81.3% vs 71.3%; hazard ratio, 1.57; 95% CI, 1.26-1.96; P < .001) and DFS (73.9% vs 63.4%; hazard ratio, 1.37; 95% CI, 1.11-1.69; P < .001) rates were significantly higher in NCIT group than in the NCRT group. The NCRT group had a higher MPR rate than that of the NCIT group (71.8% vs 61.5%), whereas the pCR rates were similar (25.9% vs 22.9%). Multivariable Cox analysis demonstrated that NCIT and MPR were independently associated with both OS and DFS. The NCIT group exhibited a lower overall recurrence rate (126 patients [23.7%] vs 190 patients [35.7%]) and distant metastasis rate (72 patients [13.5%] vs 133 patients [25.0%]), although locoregional metastasis rates were similar (98 patients [18.4%] vs 111 patients [20.9%]). Better OS and DFS were obtained for the NCIT group than for the NCRT group, regardless of whether adjuvant immunotherapy was given. Conclusions and Relevance Compared with NCRT, patients with locally advanced ESCC receiving NCIT had better 2-year OS and DFS. The decrease in distant metastasis may be the main reason, but further prospective randomized clinical trials are needed to verify this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
- Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Department of Thoracic Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, China.
Zitieren
APA
Guo, X., Chen, C., Zhao, J., Wang, C., Mei, X., Shen, J., Lv, H., Han, Y., Wang, Q., Lv, J., Chen, H., Yan, X., Liu, Z., Zhang, Z., Zhong, Q., Jiang, Y., Xu, L., Li, X., Qian, D., …, & Li, Z. (2025). Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma. JAMA Surgery, 160(5), 565. https://doi.org/10.1001/jamasurg.2025.0220
Vancouver
Guo X, Chen C, Zhao J, Wang C, Mei X, Shen J, et al. Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma. JAMA Surgery. 2025;160(5):565. doi:10.1001/jamasurg.2025.0220
BibTeX
@article{Guo2025,
author = {Guo, Xufeng and Chen, Chunji and Zhao, Jinbo and Wang, Changchun and Mei, Xinyu and Shen, Jianfei and Lv, Huilai and Han, Yongtao and Wang, Qifeng and Lv, Jiahua and Chen, Hainan and Yan, Xiaolong and Liu, Zhichao and Zhang, Zhengyang and Zhong, Qihong and Jiang, Youhua and Xu, Liwei and Li, Xiaoyang and Qian, Dong and Ma, Dehua and Ye, Minhua and Wang, Chunguo and Wang, Zimin and Lin, Jiangbo and Tian, Ziqiang and Leng, Xuefeng and Li, Zhigang},
title = {Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma},
journal = {JAMA Surgery},
year = {2025},
volume = {160},
number = {5},
pages = {565},
doi = {10.1001/jamasurg.2025.0220}
}
EUVIMED